1. Compared with the parent strain of SARS-CoV-2, the delta variant has greater
A. Transmissibility
B. Symptomology
C. Disease severity
D. Mortality
E. Unsure
2. Which of the following SARS-CoV-2 strains was most commonly isolated in the United States in July 2021?
A. Alpha
B. Beta
C. Gamma
D. Delta
E. Unsure
3. Which of the following pre-exposure measures is best for decreasing the risk of severe disease from SARS-CoV-2?
A. Masking
B. Handwashing
C. Full vaccination
D. Ivermectin
E. Unsure
4. During the delta-variant-driven surge of COVID-19 cases in summer 2021, which of these patient populations has been at highest risk for developing severe disease?
A. Partially vaccinated people
B. Fully vaccinated people
C. Unvaccinated people
D. People recovered from mild COVID-19
E. Unsure
5. Which of the following conditions has occurred in children manifested by widespread inflammation of various organs that could be fatal if not managed?
A. SARS Systemic Syndrome (SSS)
B. COVID Inflammatory Syndrome (CIS)
C. Long-term COVID-19 symptoms
D. Multisystem Inflammatory Syndrome in Children (MIS-C)
E. Unsure
6. How long should patients treated with convalescent plasma for COVID-19 wait to receive a vaccination against the disease?
A. 3 days
B. 3 weeks
C. 3 months
D. No waiting period
E. Unsure
7. Which of the following patients would be most likely to NOT have a robust response to a COVID-19 vaccine, even if receiving the full 2-dose regimen of an mRNA vaccine?
A. Patient with COPD on an inhaled bronchodilator
B. Patient with rheumatoid arthritis receiving an immunosuppressive monoclonal antibody
C. Patient with asthma who received a steroid “burst” with 5 days of prednisone 2 months ago
D. Patient with end-stage renal disease receiving 3 times weekly hemodialysis
E. Unsure
8. As of July 2021, FDA had approved booster doses for a COVID-19 vaccine manufactured by which of the following manufacturers?
A. Moderna
B. Janssen/Johnson & Johnson
C. Pfizer
D. None of above
E. Unsure
9. Which of the following monoclonal antibodies has demonstrated activity against several variants of SARS-CoV-2 and is recommended in the NIH guidelines as potential treatment option?
A. Sotrovimab
B. Bamlanivimab
C. Etesevimab
D. Imdevimab
E. Unsure
10. Which of the following medical conditions was well represented in clinical trials and is part of FDA emergency use authorization criteria for use of monoclonal antibodies for COVID-19?
A. Chronic kidney disease
B. Pregnancy
C. Obesity (body mass index >30 kg/m2)
D. Sickle cell disease
E. Unsure
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Will the information presented cause you to change your practice?
A. Yes
B. No
20. Are you committed to making these changes?
A. Yes
B. No
21. As a result of this activity, did you learn something new?
A. Yes
B. No
22. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
23. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20